Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Ibrutinib Continues to Demonstrate Impressive Efficacy/Safety

Go back to Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Ibrutinib Continues to Demonstrate Impressive Efficacy/Safety